Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Non-Current Assets (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Non-Current Assets for 6 consecutive years, with $897000.0 as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 44.87% to $897000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.7 million through Dec 2025, down 42.93% year-over-year, with the annual reading at $897000.0 for FY2025, 44.87% down from the prior year.
  • Non-Current Assets for Q4 2025 was $897000.0 at Mereo BioPharma, down from $1.2 million in the prior quarter.
  • The five-year high for Non-Current Assets was $36.5 million in Q4 2021, with the low at $897000.0 in Q4 2025.
  • Average Non-Current Assets over 5 years is $5.0 million, with a median of $2.0 million recorded in 2024.
  • The sharpest move saw Non-Current Assets crashed 93.93% in 2022, then increased 23.6% in 2023.
  • Over 5 years, Non-Current Assets stood at $36.5 million in 2021, then plummeted by 93.93% to $2.2 million in 2022, then grew by 23.6% to $2.7 million in 2023, then plummeted by 40.6% to $1.6 million in 2024, then plummeted by 44.87% to $897000.0 in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $897000.0, $1.2 million, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.